APTENSIO XR Drug Patent Profile

Which patents cover Aptensio Xr, and when can generic versions of Aptensio Xr launch?

Aptensio Xr is a drug marketed by Rhodes Pharms and is included in one NDA.

The generic ingredient in APTENSIO XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aptensio Xr

A generic version of APTENSIO XR was approved as methylphenidate hydrochloride by SPECGX LLC on November 27^th, 1998.

Summary for APTENSIO XR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	53
Clinical Trials:	4
Patent Applications:	4,334
Drug Prices:	Drug price information for APTENSIO XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for APTENSIO XR
What excipients (inactive ingredients) are in APTENSIO XR?	APTENSIO XR excipients list
DailyMed Link:	APTENSIO XR at DailyMed

See drug prices for APTENSIO XR

Recent Clinical Trials for APTENSIO XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Matthew O'Brien	Phase 4
Matthew J O'Brien, PhD, BCBA-D	Phase 4
Rhodes Pharmaceuticals, L.P.	Phase 4

See all APTENSIO XR clinical trials

Paragraph IV (Patent) Challenges for APTENSIO XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
APTENSIO XR	Extended-release Capsules	methylphenidate hydrochloride	30 mg	205831	1	2016-03-28
APTENSIO XR	Extended-release Capsules	methylphenidate hydrochloride	15 mg, 20 mg, 40 mg and 50 mg	205831	1	2015-12-28
APTENSIO XR	Extended-release Capsules	methylphenidate hydrochloride	10 mg	205831	1	2015-12-24
APTENSIO XR	Extended-release Capsules	methylphenidate hydrochloride	60 mg	205831	1	2015-12-23

US Patents and Regulatory Information for APTENSIO XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-001	Apr 17, 2015	AB3	RX	Yes	No
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-007	Apr 17, 2015	AB3	RX	Yes	Yes
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-004	Apr 17, 2015	AB3	RX	Yes	No
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-002	Apr 17, 2015	AB3	RX	Yes	No
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-003	Apr 17, 2015	AB3	RX	Yes	No
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-006	Apr 17, 2015	AB3	RX	Yes	No

Expired US Patents for APTENSIO XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-006	Apr 17, 2015	10,463,624
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-001	Apr 17, 2015	10,463,624
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-003	Apr 17, 2015	10,463,624
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-005	Apr 17, 2015	10,463,624
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-004	Apr 17, 2015	10,463,624
Rhodes Pharms	APTENSIO XR	methylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	205831-007	Apr 17, 2015	10,463,624

International Patents for APTENSIO XR

See the table below for patents covering APTENSIO XR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	268595
Australia	2122700
Canada	2355854	FORMULATIONS A LIBERATION CONTROLEE CARACTERISEES PAR UNE ACTION IMMEDIATE ET UNE DIMINUTION RAPIDE DES CONCENTRATIONS EFFICACES DE MEDICAMENTS DANS LE PLASMA (CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPIDDECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS)
Germany	69917937
Denmark	1143937
European Patent Office	1143937	FORMULATIONS A LIBERATION CONTROLEE CARACTERISEES PAR UNE ACTION IMMEDIATE ET UNE DIMINUTION RAPIDE DES CONCENTRATIONS EFFICACES DE MEDICAMENTS DANS LE PLASMA (CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS)

Last updated: July 18, 2026

APTENSIO XR Market Dynamics and Financial Trajectory: Sales Drivers, Pricing Pressure, and Patent/Competition Outlook

APTENSIO XR (amphetamine sulfate extended-release) has a constrained commercial footprint driven by ADHD prescribing dynamics, payer step therapy, pharmacist substitution realities for generic stimulants, and the low tolerance for branded premium pricing in this class. Financial trajectory is shaped by (1) rapid generic penetration typical for amphetamine XR products, (2) ongoing formulary churn across major PBMs, and (3) incremental competition from alternative stimulant delivery systems and prodrug/OTC-adjacent behaviors in patient access pathways.

Market watch checklist for investors and litigators: monitor PBM formulary status for amphetamine ER categories, track unit share versus AB-rated generic entrants, and tie any revenue inflection to (i) FDA labeling stability, (ii) documented switching/compatibility with prescriber habits, and (iii) litigation and exclusivity events affecting launch timing.

---

What is the market size exposure for APTENSIO XR in ADHD stimulant prescribing?

Target exposure: ADHD stimulant demand in the US is dominated by methyphenidate and amphetamine classes, with extended-release formulations taking the largest share of “once-daily” or “school-day coverage” prescribing.

APTENSIO XR’s commercial sensitivity is driven less by efficacy differentiation and more by access and persistence:

• Payer controls: PBM formulary tiering determines whether patients experience a cost barrier that forces switching.
• Retail pharmacy fill behavior: amphetamine XR products are frequently treated as substitutable within an AB therapeutic equivalence framework; switching can occur at the pharmacy without prescriber intent.
• Prescriber habit: clinicians often remain with a working product, but if coverage changes, “prior authorization then switch” patterns can reset share.

Featured snippet answer: In ADHD, branded XR revenue is primarily a function of formulary placement and switching friction, not clinical differentiation.

---

How do pricing, rebates, and PBM coverage typically impact branded amphetamine XR revenue?

Pricing pressure in stimulant XR categories follows a repeatable pattern:

• High rebate normalization: branded products must support competitive net pricing through rebates to stay on preferred tiers.
• Reference and substitution: when multiple AB-rated generics exist, branded net prices drift toward generic parity to prevent formulary down-tiering.
• Tier migration risk: one PBM formulary change can shift unit share quickly, even if total ADHD demand remains stable.

Operational implication for APTENSIO XR: financial trajectory is likely to track formulary tier moves and net-price compression more than baseline growth in ADHD prevalence.

---

What generic entry risks exist for APTENSIO XR and when can they accelerate?

Generic substitution risk exists whenever:

• multiple ANDA competitors secure bioequivalence and launch readiness; and
• any remaining branded exclusivity or patent coverage lapses for key listed claims (including formulation, method-of-use, or manufacturing process claims).

Generic acceleration channels:

1. AB substitution at retail: patients may switch even if the branded prescriber remains.
2. PBM switching rules: step edits or quantity limits can push patients toward the lowest net-cost equivalent.
3. Prescriber fatigue cycles: once a generic works, clinicians may standardize on it for new starts.

Featured snippet answer: branded amphetamine XR products typically face revenue compression when multiple AB-rated generics are available and PBMs shift preferred status toward lowest-net-cost equivalents.

---

What patents protect APTENSIO XR, and what does the exclusivity timeline imply for revenue?

Patent-driven exclusivity mechanics to model:

• Orphan/investigator exclusivities: not generally a main driver for ADHD stimulants unless a specific regulatory framework applies.
• New chemical entity (NCE) exclusivity: unlikely for amphetamine sulfate actives, which predate modern Orange Book frameworks.
• Use and formulation patents: extended-release technology and manufacturing parameters can delay specific generic designs, but revenue impact depends on whether competitors can design around.

Revenue relevance: even if one patent remains, generics often still gain broad access via design-arounds or challenges that let them launch with fallback positions.

Featured snippet answer: the exclusivity timeline matters only to the extent it blocks AB-equivalent supply or prevents preferred-tier listing.

---

What is the Orange Book status of APTENSIO XR and what listings drive litigation leverage?

A complete Orange Book status analysis requires itemized Orange Book listing data (US patent numbers, expiration dates, and listed drug details). No Orange Book listing dataset for APTENSIO XR is included in the provided prompt, so a definitive status and expiration timetable cannot be produced here.

What matters even without the listing table: for revenue protection, the key is whether Orange Book patents are listed to cover:

• the extended-release composition/formulation;
• the active release profile or excipient system;
• manufacturing method steps; or
• method-of-use tied to dosing or titration.

If those claims are limited or easy to design around, branded revenue typically falls faster after generic availability.

---

Which companies compete with APTENSIO XR in amphetamine extended-release ADHD treatment?

Competitive structure in ADHD amphetamine XR is usually crowded:

• multiple generic amphetamine ER products,
• alternative amphetamine delivery systems (different release technologies),
• methyphenidate ER competitors (payer cross-class switching can occur), and
• specialty/novel stimulant schedules or non-stimulant adjuncts that can move patients off stimulant regimens when coverage changes.

Commercial behavior: patients and prescribers respond to coverage and out-of-pocket cost, so the “true” competitor set includes any drug that wins payer preference or minimizes copays.

---

How does APTENSIO XR compare with other ADHD extended-release stimulants on access and switching?

Competitive comparison should be treated as an access equation:

• Net pricing and rebates (branded vs generic)
• PBM formulary tier position
• Prior authorization requirements
• Quantity limits and day supply
• Therapeutic equivalence rules and pharmacist substitution
• Holdback behavior at the wholesale level

Because the prompt does not include labeled product dosage strengths, NDCs, or PBM coverage data for APTENSIO XR, a quantified cross-product comparison cannot be reliably computed.

---

What financial trajectory indicators should investors track for APTENSIO XR?

Use indicators that correlate with unit share and net price in stimulant categories:

Revenue decomposition

• Net sales vs. units: stimulants often show volume sensitivity to formulary status.
• Net price per unit: branded net prices compress quickly with generic competition.
• Chargebacks and rebates: PBM pressure raises gross-to-net discount rates.

Supply and execution signals

• Backorder frequency: shortages can temporarily prop up revenue but rarely sustainably.
• Wholesale channel inventory: stimulants can show near-term order swings ahead of launch/PA policy changes.

Formulary and reimbursement signals

• PBM preferred tier changes
• PA denials rate trends (proxy for willingness to cover)
• Switching rates to lowest-cost AB options

---

How do patent litigation and Paragraph IV challenges affect APTENSIO XR revenue risk?

In branded stimulant portfolios, litigation impacts revenue mainly through:

• launch timing: who can enter and when,
• injunction leverage: whether court orders delay supply, and
• settlement terms: whether branded receives compensation or whether generics enter with “carve-outs” to delay direct competition.

But without APTENSIO XR-specific litigation dockets or Orange Book patent listing context, no case-by-case timeline can be asserted.

---

What FDA regulatory pathway issues matter for APTENSIO XR’s commercial durability?

For branded drugs under generic pressure, regulatory events that matter are:

• Label changes that trigger additional patent listing opportunities or change what generics can replicate.
• safety communications that drive temporary prescribing shifts.
• compatibility or manufacturing changes that can delay generic approval.

APTENSIO XR’s “commercial durability” is usually less about clinical trial strategy and more about whether regulatory changes force broad re-approvals or whether generics can proceed on existing ANDA dossiers.

---

What manufacturing and IP barriers can prevent generic supply for APTENSIO XR?

Generic entry can slow if competitors face:

• extended-release manufacturing complexity,
• stability constraints for release profile,
• higher failure rates in process validation or bioequivalence studies,
• design-around friction to avoid infringement of formulation/manufacturing method claims.

Commercial translation: even one constrained manufacturer can delay PBM switching and preserve branded share. This effect is usually temporary once multiple ANDA suppliers enter.

---

How would a generic launch scenario likely change APTENSIO XR financials?

Typical branded stimulant financial pattern after generic launch:

• Unit share drop: rapid decline as prescriptions switch to generics.
• Net price collapse: gross-to-net compression increases as branded must compete on net cost.
• Revenue stabilization attempt: branded may maintain share through contracts, patient-specific physician preference, or limited coverage carve-outs, but branded premium tends to erode.

Featured snippet answer: in amphetamine XR, a generic launch usually forces steep revenue decline and net price compression, with possible short-lived stabilization if branded retains a formulary or payer carve-out.

---

Key Takeaways

• APTENSIO XR’s revenue trajectory is dominated by access economics in ADHD stimulant markets: PBM tiering, substitution dynamics, and rebate-driven net price pressure.
• Generic entry risk is structurally high for amphetamine XR categories; the financial outcome depends on whether any Orange Book-listed patents materially block AB-equivalent competition and whether litigation delays launches.
• Most investor-relevant inflections are external to clinical performance: formulary changes, PA policy tightening or relaxation, and settlement-driven entry timing.
• The practical underwriting approach is to model revenue as a function of net price per unit and unit share under PBM formulary regimes, then stress test against generic launch and tier migration.

---

FAQs

1. How quickly do PBM formulary tier changes typically move unit share in branded ADHD stimulants?
2. What metrics best forecast net sales erosion after generic amphetamine ER entry?
3. How do pharmacist substitution and AB rating rules affect patient switching for extended-release stimulants?
4. What settlement terms in stimulant patent cases most often preserve branded revenue post-entry?
5. How do manufacturing constraints for extended-release formulations influence generic launch timing?

---

References (APA)

No cited sources were provided in the prompt, and no APTENSIO XR Orange Book, FDA, litigation, or company financial filings were included to support specific patent, regulatory, or revenue claims.